Metabolic changes associated with adaptive resistance to daptomycin in Streptococcus mitis-oralis by Parrett, Allison et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Faculty Publications -- Chemistry Department Published Research - Department of Chemistry 
2020 
Metabolic changes associated with adaptive resistance to 
daptomycin in Streptococcus mitis-oralis 
Allison Parrett 
Joseph M. Reed 
Stewart G. Gardner 
Nagendra N. Mishra 
Arnold S. Bayer 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unl.edu/chemfacpub 
 Part of the Analytical Chemistry Commons, Medicinal-Pharmaceutical Chemistry Commons, and the 
Other Chemistry Commons 
This Article is brought to you for free and open access by the Published Research - Department of Chemistry at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Faculty Publications -- 
Chemistry Department by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Authors 
Allison Parrett, Joseph M. Reed, Stewart G. Gardner, Nagendra N. Mishra, Arnold S. Bayer, Robert Powers, 
and Greg A. Somerville 
RESEARCH ARTICLE Open Access
Metabolic changes associated with
adaptive resistance to daptomycin in
Streptococcus mitis-oralis
Allison Parrett1, Joseph M. Reed2,3, Stewart G. Gardner2,4, Nagendra N. Mishra5,6, Arnold S. Bayer5,6,
Robert Powers1,7* and Greg A. Somerville2*
Abstract
Background: Viridans group streptococci of the Streptococcus mitis-oralis subgroup are important endovascular
pathogens. They can rapidly develop high-level and durable non-susceptibility to daptomycin both in vitro and
in vivo upon exposure to daptomycin. Two consistent genetic adaptations associated with this phenotype (i.e.,
mutations in cdsA and pgsA) lead to the depletion of the phospholipids, phosphatidylglycerol and cardiolipin, from
the bacterial membrane. Such alterations in phospholipid biosynthesis will modify carbon flow and change the
bacterial metabolic status. To determine the metabolic differences between daptomycin-susceptible and non-
susceptible bacteria, the physiology and metabolomes of S. mitis-oralis strains 351 (daptomycin-susceptible) and
351-D10 (daptomycin non-susceptible) were analyzed. S. mitis-oralis strain 351-D10 was made daptomycin non-
susceptible through serial passage in the presence of daptomycin.
Results: Daptomycin non-susceptible S. mitis-oralis had significant alterations in glucose catabolism and a re-
balancing of the redox status through amino acid biosynthesis relative to daptomycin susceptible S. mitis-oralis.
These changes were accompanied by a reduced capacity to generate biomass, creating a fitness cost in exchange
for daptomycin non-susceptibility.
Conclusions: S. mitis-oralis metabolism is altered in daptomycin non-susceptible bacteria relative to the
daptomycin susceptible parent strain. As demonstrated in Staphylococcus aureus, inhibiting the metabolic changes
that facilitate the transition from a daptomycin susceptible state to a non-susceptible one, inhibits daptomycin non-
susceptibility. By preventing these metabolic adaptations in S. mitis-oralis, it should be possible to deter the
formation of daptomycin non-susceptibility.
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Background
Staphylococcus aureus is the most common cause of in-
fective endocarditis (IE) in the industrialized world [1,
2]. The viridans group streptococci are the second lead-
ing IE pathogen world-wide, and the most frequent eti-
ology of IE in developing countries. Among the viridans
group streptococci, the S. mitis-oralis subgroup (i.e., S.
mitis, S. oralis, S. gordonii and S. parasanguinis) are the
predominant IE etiologies. This sub-group is therapeut-
ically problematic, as between 10 and 40% of strains ex-
hibit resistance to penicillins and/or cephalosporins,
including ceftriaxone [3, 4]. For this reason, the majority
of research into S. mitis-oralis antibiotic resistance to-
date relates to the genetic determinants of penicillin re-
sistance (e.g., [5]).
In addition to being multi-β-lactam-resistant, S. mitis-
oralis can also be vancomycin-tolerant [6], which in-
creases the use of daptomycin in treating infections
caused by such bacteria. Importantly, daptomycin non-
susceptibility arises rapidly both in vitro and in vivo
(e.g., during the treatment experimental infective endo-
carditis [7]), causing great concern this could occur in
humans undergoing daptomycin therapy for streptococ-
cal IE. In S. mitis-oralis, daptomycin non-susceptibility is
associated with mutations in cdsA and pgsA [8, 9],
genes involved in biosynthesis of membrane phospho-
lipids [10]. Specifically, these mutations in daptomycin
non-susceptible S. mitis-oralis strains result in the
loss of phosphotidylglycerol and cardiolipin from the
membrane.
Although these studies have been critical for under-
standing the genetic perturbations that facilitate S. mitis-
oralis non-susceptibility to daptomycin, the physiologic
and metabolic modifications associated with adaptive re-
sistance to daptomycin are unknown. In S. aureus, dap-
tomycin non-susceptibility has been metabolically linked
to decreased tricarboxylic acid (TCA) cycle activity, as
well as increased nucleotide synthesis and carbon flow
to pathways important for wall teichoic acid and pep-
tidoglycan biosynthesis [11]. Because S. mitis-oralis lacks
a TCA cycle and grows best in a reduced oxygen envir-
onment, it is likely the metabolic adaptations underpin-
ning daptomycin non-susceptibility are different from
those found in S. aureus. To determine the metabolic
changes associated with adaptive resistance to daptomy-
cin in S. mitis-oralis, the metabolomes of daptomycin-
susceptible strain 351 and it’s in vitro-derived daptomy-
cin non-susceptible variant, 351-D10, were analyzed
using nuclear magnetic resonance (NMR) spectroscopy.
Results
Daptomycin non-susceptibility alters growth of S. mitis
The transition of S. mitis-oralis strain 351 from a
daptomycin-susceptible state to a non-susceptible state
(strain 351-D10) during serial passage was accompanied
by a decreased growth rate (351 and 351-D10; 29 ± 1
min and 39 ± 1.5 min, respectively) and a decreased
growth yield/biomass (Fig. 1a and Supplemental Fig. 1).
This altered growth phenotype was reflected in the sig-
nificant differences in the rates of cultivation media acid-
ification (Fig. 1b). As expected, the growth changes also
decreased glucose depletion from the medium contain-
ing strain 351-D10 relative to that of strain 351 (Fig. 1c
and Supplemental Fig. 2). Importantly, the total amount
of glucose consumed by both strains was equivalent, yet
the difference in biomass between the two strains was
significant, suggesting that growth alone did not account
for all the differences in glucose consumption. The
glycolytic end-product of glucose is pyruvate, which, in
S. mitis-oralis, is predominantly catabolized by the
membrane-associated lactate dehydrogenase [12]. The
lactic acid produced by lactate dehydrogenase accumu-
lated in the cultivation media, which caused the pH of
the media to decrease over time (Fig. 1b and d). Similar
to the depletion of glucose from the media, the accumu-
lation of lactate in the media was largely dependent on
bacterial growth (Fig. 1d and Supplemental Fig. 2).
Taken together, the transition of S. mitis-oralis to a dap-
tomycin non-susceptible state was accompanied by sig-
nificant fitness changes resulting from impaired growth,
and, likely, altered metabolism.
The transition to a daptomycin non-susceptible state
significantly alters metabolism
The growth profiling of S. mitis-oralis strains 351 and
351-D10 suggests metabolism was altered during the
transition to a daptomycin non-susceptible state. To as-
sess the extent of metabolic alterations, ten independent
replicates of cell-free lysates from strains 351 and 351-
D10 cultivated with 13C-glucose were harvested, the 1D
1H NMR spectra were collected, and the spectra were
analyzed by PCA (Fig. 2). To normalize the metabolomic
samples for the dissimilar growth kinetics of the two
strains, and to ensure the metabolomes represented
equivalent growth phases, bacteria were harvested at
different cultivation times (i.e., 2 h for strain 351 and
2 h 45 min for strain 351-D10). As expected, the PCA
scores plot revealed that daptomycin susceptible and
non-susceptible strains each formed well-separated
clusters (Fig. 2), confirming that significant metabolic
differences arose during the transition to daptomycin
non-susceptibility.
The PCA scores plot established significant metabolic
differences existed between daptomycin-susceptible and
non-susceptible S. mitis-oralis strains (Fig. 2), and the
growth profiles indicated these differences were likely re-
lated to the enzymatic processing of glucose (Fig. 1c and
d). To assess the differences in glucose catabolism and
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downstream pathways between strains 351 and 351-D10,
the bacterial cell-free lysates used in the PCA analysis
were analyzed by collecting 2D 1H- 13C HSQC NMR
(Fig. 3 and Supplemental Fig. 3). Consistent with the
growth profiles, S. mitis-oralis strain 351-D10 had sig-
nificantly decreased intracellular levels of activated glu-
cose (i.e., UDP-glucose) and lactic acid relative to strain
351 (Fig. 3). In contrast, strain 351-D10 had a signifi-
cantly greater level of acetic acid, indicating that pyru-
vate generated from glycolysis was used for substrate-
level phosphorylation as opposed to almost exclusively
being used for the oxidation of NADH via lactate de-
hydrogenase. This difference was consistent with de-
creased GAPDH activity in strain 351-D10 (Fig. 4).
Decreased GAPDH activity would slow the accumula-
tion of NADH, but also decrease glycolytic ATP
synthesis. As mentioned, strain 351-D10 likely offsets
the decrease in glycolytic ATP synthesis through sub-
strate phosphorylation via the phosphotransacetylase/
acetate kinase pathway (Fig. 3).
Discussion
Most studies of antibiotic resistance/non-susceptibility
focus on genetic, transcriptional, and occasionally prote-
omic analyses [5, 8, 10]. These studies can provide valu-
able information; however, they describe changes that
are predicted to occur (e.g., gene transcription does not
necessarily equate with protein translation or activity).
In contrast, metabolomics provides insight into cellular
changes that have actually occurred and are likely to
contribute to antibiotic non-susceptibility. Because
metabolic pathways are finite in number, it is possible to
Fig. 1 Growth characteristics of S. mitis-oralis strains 351 (black symbols, solid line) and 351-D10 (grey symbols, dashed line) cultivated in BHI with
2 g/L of supplemental glucose. The A600 (a) and pH (b) profiles were assessed every 30 min. Glucose depletion (c) and lactate accumulation (d) in
the cultivation media were assessed hourly. Data are representative of the mean of experiments performed in biological triplicate, with error bars
representing the standard deviation of the mean. Statistical differences in A600 and pH for strain 351 relative to strain 351-D10 was assessed by
ANOVA. A statistically significant difference (p ≤ 0.01) is represented with an (*)
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‘work backwards’ from the profile of altered metabolites
and determine where the alterations arose.
In S. aureus, daptomycin non-susceptibility can be me-
diated by genetic changes in mprF, walKR, rpoB, and
rpoC [13–16], changes in cell membrane composition
[17, 18], and/or metabolic adaptations [11]. The meta-
bolic adaptations in S. aureus cause a redirection of car-
bon flow from the TCA cycle into the pentose
phosphate pathway. This redirection of carbon increases
the availability of essential intermediates for the biosyn-
thesis of peptidoglycan, wall teichoic acids, and nucleo-
sides/nucleotides. These metabolic changes pre-adapt
daptomycin non-susceptible S. aureus for daptomycin
challenge. In other words, daptomycin challenge causes
only minimal metabolic perturbations, which minimizes
the fitness cost of daptomycin non-susceptibility [11].
The more likely reason for the minimal metabolic
changes and low fitness cost associated with daptomycin
non-susceptibility in S. aureus is due to its relatively ro-
bust metabolic capabilities, including the full comple-
ment of central metabolism pathways [19, 20]. In
contrast, S. mitis-oralis lacks the central metabolism
TCA cycle, creating metabolic deficiencies that require
supplementation from the medium or a host. Alterations
in the more modest metabolic capabilities of S. mitis-
oralis would be consistent with profound growth differ-
ences between the susceptible and non-susceptible
strains (Fig. 1).
The growth differences between daptomycin suscep-
tible and non-susceptible S. mitis-oralis strains are indi-
cative of significant metabolic changes. Metabolomics
revealed these growth differences coincided with signifi-
cant metabolic changes (Fig. 2). Most importantly, is an
alteration in how glucose is catabolized (Figs. 1, 3, and
4). For a lactic acid bacterium, alterations in glycolysis
and/or lactate dehydrogenase activity creates the prob-
lem of how to produce ATP and maintain the redox sta-
tus. Generating ATP by substrate-level phosphorylation
has the advantage of not reducing NAD+, which de-
creases the burden on lactate dehydrogenase to balance
the redox state, although it does not eliminate the need
to oxidize dinucleotides. In addition to differences in
ATP generation, the altered/delayed glucose catabolism
allows for the diversion of carbon into other metabolic
pathways (Figs. 3 and 5), which can enable metabolic ad-
aptations that overcome altered glucose utilization. In
contrast to S. aureus, S. mitis did not shunt carbon into
the oxidative branch of the pentose phosphate pathway,
which would generate NADPH. This latter point further
indicates that these metabolic changes are driven by the
bacterial redox status.
In daptomycin non-susceptible S. mitis-oralis, the
metabolomics data revealed that glucose carbons were
more slowly catabolized through glycolysis and lactate
dehydrogenase relative to the daptomycin-susceptible
strain (Figs. 1 and 3). As the primary function of lactate
Fig. 2 The PCA scores plot was generated from 1D 1H NMR spectra collected using cell-free lysates of S. mitis-oralis strains 351 (blue) and 351-
D10 (red) cultivated in BHI with 2 g/L of supplemental 13C-glucose and harvested at 2 h (351) or 2 h 45min (351-D10). The R2 and Q2 are 0.931
and 0.781 respectively for the PCA model
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dehydrogenase is maintaining redox balance, it is likely a
dysregulation in redox status contributed to the slower
growth of strain 351-D10. One possibility for maintain-
ing the redox status is by funneling carbon through
amino acid biosynthetic pathways that oxidize more di-
nucleotides (e.g., branched chain amino acids, glutamate,
and alanine) than they reduce (e.g., serine) (Fig. 5). Fun-
neling more carbon through amino acid synthesis can be
done in such a way as to facilitate the oxidation of dinu-
cleotides, but the ATP deficit created by decreasing car-
bon flow through glycolysis also needs to be offset. The
increase in acetic acid strongly suggests the ATP deficit
is balanced by substrate-level phosphorylation through
the phosphotransacetylase/acetate kinase pathway.
Taken together, these data suggest the transition of S.
mitis-oralis to a daptomycin non-susceptible state is ac-
companied by changes in redox balance, ATP synthesis,
and carbon utilization. The extent to which these meta-
bolic changes confer daptomycin non-susceptibility, or
are a consequence of mutations arising in phospholipid
biosynthetic genes, remains to be determined. In
addition, the contribution of each daptomycin-induced
mutation to the metabolic changes remains to be deter-
mined. Lastly, an important unanswered question is
whether these metabolic changes in daptomycin-non-
susceptible S. mitis-oralis strains be exploited to prevent
or overcome this phenotype, as demonstrated in
daptomycin-non-susceptible S. aureus [21, 22]? On this
point, metabolic adaptations that facilitate non-
susceptibility to vancomycin and daptomycin have suc-
cessfully been targeted in S. aureus to prevent the devel-
opment of non-susceptibility and to re-sensitize non-
susceptible bacteria to these antibiotics [21, 22]. This
strategy has relied on using inhibitors of metabolic path-
ways important for non-susceptibility such that enzym-
atic activity is reduced to the point where it becomes
detrimental to the development or maintenance of non-
susceptibility. Similar success with S. mitis-oralis will
likely target amino acid biosynthesis and/or glycolysis,
but this work is on-going.
Fig. 3 Heatmap with hierarchal clustering of metabolomic differences between S. mitis-oralis strains 351 and 351-D10. The map was generated
using 2D 1H 13C HSQC NMR spectra with normalized peak intensities. Statistical significance was calculated using Student’s t-test (* p < 0.05 and
** p < 0.001) or Student’s t-test with Benjamini-Hochberg correction for multiple hypothesis (the asterisk in blue)
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Fig. 4 GAPDH activity in S. mitis-oralis strain 351-D10 is significantly reduced relative to strain 351. GAPDH activity was measured in S. mitis-oralis
cell lysates from cultures cultivated in BHI and harvested after 1.5 h (351) or 2.5 h (351-D10). The data represent the mean and standard deviation
from the mean of 3 biological replicates. Statistical significance (**) was assessed using Student’s t-test (p ≤ 0.05)
Fig. 5 Summary of metabolic changes between S. mitis-oralis strains 351 and 351-D10. Green upward arrows represent a metabolite whose concentration
is increased in strain 351-D10 relative to those in strain 351. Red downward arrows represent metabolites that are decreased in strain 351-D10 relative to
that in strain 351. Metabolites in gray represent intermediates that were not observed in the NMR spectra, but were inferred from secondary metabolites
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Conclusions
Significant metabolic changes accompany the develop-
ment of a daptomycin non-susceptible state in S. mitis.
These changes alter the bacterial ability to utilize glu-
cose. This is a significant observation because S. mitis,
like most lactic acid bacteria, is heavily dependent upon
glycolysis and lactate dehydrogenase to balance the
redox state and provide energy and biosynthetic inter-
mediates. Because these changes occur in an essential
metabolic pathway, it should be possible to target gly-
colysis using drugs that increase stress on this pathway
(e.g., oxamic acid) and prevent the development of dap-
tomycin non-susceptibility and to re-sensitize non-
susceptible bacteria to daptomycin.
Methods
Bacterial strains and cultivation conditions
S. mitis-oralis daptomycin-susceptible strain 351 (dapto-
mycin MIC = 0.5 μg/ml) and its daptomycin non-
susceptible derivative, 351-D10 (daptomycin MIC >
256 μg/ml), were used for metabolomic analysis [8]. S.
mitis-oralis strain 351 was isolated from a patient with
endocarditis [7] and the derivative strain 351-D10 was
generated by in vitro serial passage of strain 351 for 10
days in medium containing 20 μg/ml of daptomycin [8].
Whole-genome sequencing of the two strains revealed
that strain 351-D10 had accrued mutations at seven loci;
specifically, orfs sm351–26 (cdsA), sm351–42 (rpoB),
sm351–129 (fni), sm351–251 (unknown), sm351–669
(pepT), sm351–1076 (rbn), and sm351–1167 (clpX). S.
mitis strains were cultivated in Bacto Brain Heart Infu-
sion medium (BHI), BHI + 2 g/L D-Glucose (BHI + glu-
cose), BHI + 2 g/L 13C-D-Glucose (BHI + 13C-glucose),
or on blood agar (TSA with Sheep Blood). Bacterial pre-
cultures were inoculated 1:100 from overnight cultures
into 50mL of BHI in a 50 mL conical tube and incu-
bated at 37 °C, without aeration, for 4 h. These exponen-
tial growth phase pre-cultures were centrifuged for 5
min at 4500 rpm (3460.7 X g) at 22 °C and suspended in
2–3 mL of medium. Primary cultures were inoculated
into 50 mL pre-warmed BHI, BHI + 2 g/L D-Glucose, or
BHI + 2 g/L 13C-Glucose in a 50mL conical tube, at an
absorbance at 600 nm (A600) of 0.08, and incubated at
37 °C. The cultures were mixed by inversion every 30
min prior to sampling. The A600 and pH were recorded
every 30 min for 5 h.
Determination of glucose and lactate concentrations in
cultivation media
Cultivation media were harvested hourly (1 mL) by cen-
trifugation at 13,200 rpm (16,168 x g), for 5 min at 4 °C.
The cell-free media were transferred to 1.5 mL micro-
centrifuge tubes, flash frozen in liquid nitrogen, and
stored at − 20 °C until use. Glucose and lactate
concentrations in the culture media were determined
from three independent cultures with kits purchased
from R-Biopharm (Glucose test kit, #10716251035 and
L-Lactic acid test kit, #10139084035).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
activity assay
Due to differences in growth, bacteria were cultivated in
BHI for 1.5 h (strain 351) or 2.5 h (strain 351-D10) and
harvested by centrifugation at 5000 rpm (4272.5 x g) for
5 min at 4 °C. Supernatants were discarded and the cell
pellets were suspended in 750 μL GAPDH assay buffer
(BioVision, Inc) and lysed in lysing matrix B tubes using
a FastPrep instrument. The lysates were centrifuged at
13,200 rpm (16,168 x g), for 5 min at 4 °C. Supernatants
were transferred to pre-chilled 1.5 mL microcentrifuge
tubes. GAPDH activity was determined from three inde-
pendent cultures according to the manufacture’s instruc-
tion. Protein concentrations were determined using the
Modified Lowry Protein Assay (Fisher Scientific). The
harvest times and corresponding A600 units were differ-
ent from those used in metabolomics experiments be-
cause excess glucose was not added to the cultivation
medium for enzyme assays.
NMR sample preparation
The preferred process for performing 13C-glucose meta-
bolomics experiments is to use a glucose-free medium
and add labelled glucose at a defined concentration. Un-
fortunately, glucose-free BHI was unavailable. Adding 2
g/L of 13C-glucose into BHI containing unlabeled glu-
cose (2 g/L) meant that only 50% of the glucose was la-
beled. This limitation required the doubling of the
number of bacteria harvested. Harvest times were
chosen based on A600 numbers that gave maximal bio-
mass, when most of the glucose was catabolized, but not
when the bacteria were in the stationary phase. For these
reasons, bacteria were harvested at two different times
when the bacterial biomass was equivalent. Bacteria cul-
tivated in BHI + 13C-glucose were grown for 2 h (351) or
2 h 45 min (351-D10) and harvested by centrifugation at
4500 rpm (3460.7 x g) for 5 min at 0 °C. Bacterial cell
pellets were washed with ice cold ultrapure H2O (Milli-
Q) and quenched in liquid nitrogen. Cells were placed
on ice to thaw for 5 min and the cell pellets were sus-
pended in 1 mL of ice cold ultrapure H2O. The A600 of
the bacterial suspension was determined and 60 A600
units were diluted into 1 mL of ultrapure H2O. The sam-
ples were transferred to lysing matrix B tubes (MP Bio-
medicals) and lysed for 40 s using a FastPrep instrument
at a speed setting of 6, then placed on ice for 5 min. The
lysing matrix B tubes were centrifuged at 13,200 rpm
(16,168 x g) for 5 min at 0 °C, and the supernatants were
transferred to 2 mL microcentrifuge tubes pre-cooled to
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0 °C. Ice-cold H2O (1 mL) was added to each lysing
matrix B tube, vortexed, and the samples were lysed a sec-
ond time. The lysing matrix B tubes were centrifuged for
5min at 0 °C, and the supernatants were pooled. The
pooled cell-free lysates were clarified by centrifugation at
13,200 rpm for 1min at 0 °C. Approximately 1.3 mL of the
cell-free lysate from each sample was transferred to a pre-
chilled 1.5mL microcentrifuge tube. 1 mL of each cell-free
lysate was flash frozen in liquid nitrogen and stored at −
80 °C prior to lyophilization for NMR analysis. The
remaining cell-free lysate, approximately 300 μL, was used
to determine protein concentrations (for normalization)
with a modified Lowry protein assay (Fisher Scientific).
Lyophilized frozen cell-free lysates were, suspended in
190 μL of 50mM phosphate buffer (pH = 7.2, uncor-
rected) in D2O, and 50 μM of 3-(trimethylsilyl)propionic-
2,2,3,3-d4 acid sodium salt (TMSP) was added as a chem-
ical shift reference. The samples were centrifuged for 20
min at 13,200 rpm and 0 °C to remove any remaining cell
debris. The supernatants were transferred to 3mm NMR
tubes for data collection.
NMR data collection and analysis
NMR spectra were collected at 298 K using a Bruker
AVANCE III-HD 700MHz spectrometer equipped with
a 5 mm quadruple resonance QCI-P cryoprobe (1H, 13C,
15N, and 31P) with z-axis gradients. A SampleJet sample
changer, an automatic tuning and matching accessory,
and ICON-NMR software were used to automate the
NMR data collection. The 1D 1H NMR spectra were col-
lected with 32 K data points, 128 scans, 16 dummy
scans, a relaxation delay of 1.5 s, and a spectral width of
11,160 Hz. The 1D 1H NMR spectra were collected
using an excitation sculpting pulse sequence to suppress
the water resonance [23]. The 2D 1H- 13C HSQC spectra
were collected using non-uniform sampling (NUS) at a
25% sampling sparsity [24]. The 2D 1H- 13C HSQC spec-
tra were acquired with 32 scans, 16 dummy scans, and a
1.5 s relaxation delay. The spectra were collected with 2
K data points and a spectral width of 11,160 Hz in the
direct dimension, and 1 K data points and a spectral
width of 29,059 Hz in the indirect dimension.
NMR data processing and analysis
Our MVAPACK software suite (http://bionmr.unl.edu/mva-
pack.php) was used to process and analyze the 1D 1H NMR
spectra [25]. The 1D 1H NMR spectra were processed with a
single zero-fill and a 0.3Hz line-broadening, and then Fourier
transformed and automatically phased-corrected [26]. The
1D 1H NMR spectra were normalized with standard normal
variate normalization, aligned using icoshift [27], and then
referenced to the TMSP peak at 0 ppm. Noise regions were
automatically removed from the spectra and the residual
water signal (4.6–4.8 ppm) was manually removed. The 1D
1H NMR spectra were binned using adaptive intelligent bin-
ning [28] and scaled using unit variance (UV) scaling. The
resulting data matrix was then used to create a principle
component analysis (PCA) model.
NMRpipe [29] was used to process the 2D 1H-13C
HSQC data set and NMRViewJ [30] was used to analyze
the spectra and assign the metabolites. The Human Meta-
bolomic Database (HMDB) (http://www.hmdb.ca/) was
used to assign metabolites by matching reference chemical
shifts from the database to the experimental spectra using
a peak-error tolerance of 0.08 ppm and 0.25 ppm for 1H
and 13C chemical shifts, respectively [31]. A data matrix
consisting of relative metabolite peak intensities (rows)
and biological replicates (columns) was produced from
the 2D 1H-13C HSQC data set [32, 33]. The data matrix
was normalized using probabilistic quotient (PQ)
normalization [32, 33]. BioCyc (https://biocyc.org) was
used to identify the dysregulated S. mitis metabolic path-
ways based on the observed metabolite changes [34].
Statistical analysis
Growth profiles and assays were performed in triplicate.
Statistical differences in growth profiles were assessed by
ANOVA, where a p ≤ 0.01 was defined as statistically
significant. Statistical differences in assays were assessed
by Student’s t-test, where a p ≤ 0.05 was defined as sta-
tistically significant.
A pair-wise Student’s t-test was used to determine if
strain-dependent alterations in metabolite concentrations
were statistically significant. The p-values were corrected
using the Benjamini-Hochberg procedure to minimize the
false discovery rate for multiple hypothesis testing [35].
Metabolite concentration changes were determined to be
statistically significant by an FDR corrected p-value < 0.05.
In order to visualize the differences between S. mitis
strains, MetaboAnalyst (https://www.metaboanalyst.ca)
was used to generate a heatmap with hierarchical cluster-
ing from the 2D 1H-13C HSQC NMR peak intensities
[36]. The data matrix of NMR peak intensities was scaled
along each row using standard normal variate (SNV).
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